Research programme: cell penetrating alphabodies - Complix/Jiangsu Nhwa Pharmaceutical
Latest Information Update: 08 Aug 2021
At a glance
- Originator Complix; Jiangsu Nhwa Pharmaceutical
- Class Neuroprotectants; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders